ClinicalTrials.gg
CompletedNCT02745860Updated Feb 3, 2025

Comparison of Two Dose Strengths of Selexipag in Healthy Adults

A Phase 1 interventional study of Selexipag (adult formulation) and Selexipag (pediatric formulation) in Healthy Subjects, sponsored by Actelion. Completed. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-03.

Sponsored by Actelion (part of Johnson & Johnson) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

Clinical study in healthy adult subjects to compare the adult tablet of selexipag with the tablet developed for children.

Read the detailed description

Healthy male adults receive a single dose of selexipag (200 µg) but using a different tablet strength (4 film-coated pediatric tablets of 50 µg versus one film-coated tablet of 200 µg selexipag) during each of the two study periods. There is a washout of 7-9 days between the two study treatment administrations.

02

Conditions studied

  • Healthy Subjects

Keywords

  • selexipag
  • pharmacokinetics
03

In context

Lead sponsor

Actelion is the lead sponsor of 143 studies on the registry; 1 is open to participants now.

Of its 28 completed or terminated interventional studies of FDA-regulated products, 25 (89%) have results posted.

First submitted before Actelion became part of Johnson & Johnson.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Eligibility criteria

Key inclusion Criteria:

  • Male subjects aged from 18 to 45 years (inclusive) at screening
  • Signed form
  • (BMI) between 18.0 and 28.0 kg/m2 (inclusive) at screening
  • Healthy on the basis of physical examination,cardiovascular assessments and laboratory tests

Key exclusion Criteria:

  • Any to the study treatments
  • History or clinical evidence of any disease or medical / surgical condition or treatment, which may put the subject at risk of participation in the study or may interfere with the absorption, distribution, metabolism or excretion of the study treatments
  • Any circumstances or conditions, which, in the opinion of the investigator, may affect the subject's full participation in the study or compliance with the protocol
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Sequence AB

    Subjects receive 200 µg of selexipag (adult formulation) as a single oral dose during Period 1 and 200 µg of selexipag (pediatric formulation) as a single oral dose during Period 2

    Drug: Selexipag (adult formulation) · Drug: Selexipag (pediatric formulation)

  • Experimental
    Sequence BA

    Subjects receive 200 µg of selexipag (pediatric formulation) as a single oral dose during Period 1 and 200 µg of selexipag (adult formulation) as a single oral dose during Period 2

    Drug: Selexipag (adult formulation) · Drug: Selexipag (pediatric formulation)

Interventions

06

What researchers measure

Primary outcomes

  1. Area under plasma concentration-time curve [AUC(0-inf)] of selexipag and ACT-333679

    AUC(0-inf) is the area under plasma concentration-time curves for selexipag and its metabolite (ACT-333679), calculated from zero to the extrapolated infinite time

    Time frame: From predose until 72 hours postdose for each treatment period

  2. Maximum plasma concentration (Cmax) of selexipag and ACT-333679

    Cmax is directly derived from the individual plasma concentration time curves for selexipag and its metabolite ACT-333679

    Time frame: From predose until 72 hours postdose for each treatment period

Secondary outcomes

  1. Time to reach Cmax (tmax) of selexipag and ACT-333679

    tmax is directly derived from the individual plasma concentration time curves for selexipag and its metabolite ACT-333679

    Time frame: From predose until 72 hours postdose for each treatment period

  2. Terminal half-life (t½) of selexipag and ACT-333679

    The period of time required for the concentration levels of selexipag or its metabolite (ACT-333679) to be reduced by one-half

    Time frame: From predose until 72 hours postdose for each treatment period

  3. Area under plasma concentration-time curve [AUC(0-t)] of selexipag and ACT-333679

    AUC(0-t) is the area under plasma concentration-time curves for selexipag and its metabolite (ACT-333679), calculated from zero to time t of the last measured concentration above the limit of quantification

    Time frame: From predose until 72 hours postdose for each treatment period

  4. Incidence of treatment-emergent adverse events and serious adverse events

    A treatment-emergent AE is any AE temporally associated with the use of a study treatment, whether or not considered related to the study treatment, including any abnormalities in ECG parameters, vital signs or laboratory tests

    Time frame: From first administration of selexipag (Day 1 Period 1) to end of study (Day 4, Period 2)

  5. Incidence of safety events of interest

    Events of interest include any abnormalities in ECG, vital signs or laboratory test results

    Time frame: From first administration of selexipag (Day 1 Period 1) to end of study (Day 4, Period 2)

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Boehler M, Bruderer S, Ulc I, Dingemanse J. Biocomparison Study of Adult and Paediatric Dose Strengths of the Prostacyclin Receptor Agonist Selexipag. Eur J Drug Metab Pharmacokinet. 2018 Feb;43(1):115-120. doi: 10.1007/s13318-017-0424-z. PubMed 28639216 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2016, a primary completion of Jun 2016 and a completion of Jun 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 18, 2016
First posted
Apr 20, 2016
Start
Jun 2016
Primary completionActual
Jun 2016
CompletionActual
Jun 2016
Last update
Feb 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02745860
Lead sponsor
Actelion
Responsible party
Sponsor
First posted
Apr 20, 2016
Start date
Jun 2016
Primary completion
Jun 2016
Completion
Jun 2016
Last update
Feb 3, 2025

Study contacts

Margaux Boehler
Actelion

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Selexipag

Start the discussion